rheumatoid%20arthritis
RHEUMATOID ARTHRITIS

Rheumatoid arthritis is a systemic autoimmune rheumatic disorder of unknown etiology.
It is the most common form of inflammatory arthritis.
Patient usually complains of joint pain and/or swelling with morning stiffness that lasts for more than an hour.

Goals of treatment are clinical & radiological remission of disease and to reduce functional limitations & permanent joint damage.

Follow Up

Monitoring for Drug Toxicity

  • Eg complete blood count, serum creatinine, liver function tests, hepatitis B and C screening, ophthalmologic exam, latent tuberculosis screening (for biological DMARDs, with chest X-ray)
  • Recommended prior to resuming or increasing therapy with DMARDs
  • It is important to monitor for toxicity due to the potential risks of serious adverse effects of DMARDs

Tapering of Therapy

  • Should be considered if there is disease remission with biological DMARDs therapy of at least 6 months
    • Glucocorticoid dose should be tapered first prior to reduction of dose of biological DMARDs
  • To decrease risk of flares, gradual withdrawal of biological therapies should be done
    • Flare risk is inversely proportional to disease activity and sustained response duration
  • In persistent remission of at least 12 months, biological DMARDs should be slowly tapered by expanding the interval between doses or dose reduction, while continuing conventional synthetic DMARDs
  • Ceasing treatment with conventional synthetic DMARDs is associated with increased flare frequency, hence tapering should be done cautiously and should be evaluated rigorously

Disease Activity Monitoring

  • Disease activity should be measured and documented regularly
    • Moderate-high disease activity: Monthly
    • Sustained low disease activity: Every 6 months
    • Clinical remission: Every 6 months (with DAS and DAS28)
    • Sustained remission: Every 3-6 months
  • Consider structural changes, comorbidities, and functional impairment when formulating treatment decisions on follow-ups
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 10 Apr 2019
Treatment with tofacitinib yields significant improvements in signs and symptoms of rheumatoid arthritis (RA) in patients from the Asia Pacific, according to data from a posthoc analysis. The drug has a safety profile consistent with global tofacitinib studies, although infections occur more frequently in Asians.
Jairia Dela Cruz, 30 Apr 2019
In rheumatoid arthritis (RA) patients in remission, increasing the dose interval of tocilizumab injection from the standard 162 mg once weekly to twice weekly may do more harm than good. Specifically, such a strategy is associated with a lower chance of remission maintenance as well as a lack of improvement in tolerability, as shown in a recent trial.
Jairia Dela Cruz, 29 Apr 2019
Physicians are likely to underestimate the severity of psoriatic arthritis (PsA) in patients who are older, show higher fatigue levels, complain of greater pain or have poorer mental health, according to a Singapore study. In contrast, overestimation of disease severity by physicians tends to occur in the presence of higher swollen joint counts.
Jairia Dela Cruz, 05 Jan 2017
Patients with early arthritis should be allowed to share in the decision making regarding the approach to treatment, with rheumatologists acting as the primary specialists, according to the 2016 update of the European League Against Rheumatism (EULAR) recommendations for early arthritis management.